Ignite Creation Date:
2025-12-26 @ 10:46 PM
Ignite Modification Date:
2026-04-08 @ 12:55 PM
Study NCT ID:
NCT00116012
Status:
COMPLETED
Last Update Posted:
2006-11-29
First Post:
2005-06-26
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Anticoagulation With rNAPc2 to Eliminate MACE/TIMI 32
Sponsor:
ARCA Biopharma, Inc.
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Coronary Disease | View |
Keywords:
Keywords
| Keyword Brief | Keyword Text | View |
|---|---|---|
| None | acute coronary syndrome | View |
| None | rNAPc2 | View |
| None | unstable angina | View |
| None | Non-STE myocardial infarction | View |
| None | ST elevation | View |
| None | cardiac enzymes | View |
| None | acute coronary syndromes | View |
| None | factor VIIa | View |
| None | tissue factor | View |
| None | nematode anticoagulant protein c2 | View |
| None | anticoagulants | View |
| None | thrombin inhibitors | View |
| None | thrombosis | View |